Cargando…

Drug-induced liver injury due to tofacitinib: a case report

BACKGROUND: Drug-induced liver injury is an acute or chronic liver damage in response to drugs, herbals, and any chemical compound. CASE PRESENTATION: In the present work, liver failure following the use of tofacitinib was reported. The patient was an 18-year-old iranian woman without any history of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mardani, Masoud, Mohammadshahi, Jafar, abolghasemi, Sara, Teimourpour, Roghayeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024406/
https://www.ncbi.nlm.nih.gov/pubmed/36932434
http://dx.doi.org/10.1186/s13256-023-03821-4
_version_ 1784909094983827456
author Mardani, Masoud
Mohammadshahi, Jafar
abolghasemi, Sara
Teimourpour, Roghayeh
author_facet Mardani, Masoud
Mohammadshahi, Jafar
abolghasemi, Sara
Teimourpour, Roghayeh
author_sort Mardani, Masoud
collection PubMed
description BACKGROUND: Drug-induced liver injury is an acute or chronic liver damage in response to drugs, herbals, and any chemical compound. CASE PRESENTATION: In the present work, liver failure following the use of tofacitinib was reported. The patient was an 18-year-old iranian woman without any history of underlying disease. She complained of alopecia areata, and tofacitinib was administered for disease management. Following adherence to tofacitinib medication, partial recovery was obtained. At the time of hospitalization, the patient had a stable condition and only anorexia, jaundice, and elevation of liver enzymes were reported. During hospitalization, liver injury progressed and liver transplantation was suggested. After drug-induced liver injury diagnosis, the use of the drug was discontinued and the patient underwent supportive treatment. The patient recovered without any severe sequelae. CONCLUSIONS: Tofacitinib is a Janus kinase inhibitor that is useful in the treatment of disorders such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Until now, the severe side effect of this drug has not been reported and in most cases it is used as a last resort, but here we report a rare side effect of this drug.
format Online
Article
Text
id pubmed-10024406
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100244062023-03-19 Drug-induced liver injury due to tofacitinib: a case report Mardani, Masoud Mohammadshahi, Jafar abolghasemi, Sara Teimourpour, Roghayeh J Med Case Rep Case Report BACKGROUND: Drug-induced liver injury is an acute or chronic liver damage in response to drugs, herbals, and any chemical compound. CASE PRESENTATION: In the present work, liver failure following the use of tofacitinib was reported. The patient was an 18-year-old iranian woman without any history of underlying disease. She complained of alopecia areata, and tofacitinib was administered for disease management. Following adherence to tofacitinib medication, partial recovery was obtained. At the time of hospitalization, the patient had a stable condition and only anorexia, jaundice, and elevation of liver enzymes were reported. During hospitalization, liver injury progressed and liver transplantation was suggested. After drug-induced liver injury diagnosis, the use of the drug was discontinued and the patient underwent supportive treatment. The patient recovered without any severe sequelae. CONCLUSIONS: Tofacitinib is a Janus kinase inhibitor that is useful in the treatment of disorders such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Until now, the severe side effect of this drug has not been reported and in most cases it is used as a last resort, but here we report a rare side effect of this drug. BioMed Central 2023-03-18 /pmc/articles/PMC10024406/ /pubmed/36932434 http://dx.doi.org/10.1186/s13256-023-03821-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Mardani, Masoud
Mohammadshahi, Jafar
abolghasemi, Sara
Teimourpour, Roghayeh
Drug-induced liver injury due to tofacitinib: a case report
title Drug-induced liver injury due to tofacitinib: a case report
title_full Drug-induced liver injury due to tofacitinib: a case report
title_fullStr Drug-induced liver injury due to tofacitinib: a case report
title_full_unstemmed Drug-induced liver injury due to tofacitinib: a case report
title_short Drug-induced liver injury due to tofacitinib: a case report
title_sort drug-induced liver injury due to tofacitinib: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024406/
https://www.ncbi.nlm.nih.gov/pubmed/36932434
http://dx.doi.org/10.1186/s13256-023-03821-4
work_keys_str_mv AT mardanimasoud druginducedliverinjuryduetotofacitinibacasereport
AT mohammadshahijafar druginducedliverinjuryduetotofacitinibacasereport
AT abolghasemisara druginducedliverinjuryduetotofacitinibacasereport
AT teimourpourroghayeh druginducedliverinjuryduetotofacitinibacasereport